Evidence map›Paper›PMID 41258220›Full record

ArticleNPJ Parkinson's disease2025

Neuropsychological insights into creativity in people with Parkinson's disease.

Sara Zeggio, David Steyrl, Matthew Pelowski, Paul Krack, Sirwan K L Darweesh, Julia S Crone, Bastiaan R Bloem, Marjan J Meinders, Blanca T M Spee

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara ZeggioDepartment of Neurology, Radboud University Medical Center; Donders Institute for Brain, Cognition and Behavior; Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands.
David SteyrlDepartment of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna, Vienna, Austria.
Matthew PelowskiDepartment of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna, Vienna, Austria.
Paul KrackDepartment of Neurology, University Hospital Bern, Inselspital, Bern, Switzerland.
Sirwan K L DarweeshDepartment of Neurology, Radboud University Medical Center; Donders Institute for Brain, Cognition and Behavior; Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands.
Julia S CroneDepartment of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna, Vienna, Austria.
Bastiaan R BloemDepartment of Neurology, Radboud University Medical Center; Donders Institute for Brain, Cognition and Behavior; Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands.
Marjan J MeindersDepartment of Neurology, Radboud University Medical Center; Donders Institute for Brain, Cognition and Behavior; Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands.
Blanca T M SpeeDepartment of Neurology, Radboud University Medical Center; Donders Institute for Brain, Cognition and Behavior; Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands. blanca.spee@univie.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Creativity, the capacity and motivation to produce novel and personally meaningful ideas or behaviors, can be influenced by Parkinson's disease (PD). Non-motor neuropsychological symptoms, such as apathy and negative schizotypy have been linked to reduced creativity, while dopaminergic treatments are associated with increased creative engagement. Building on epidemiological findings investigating changes in creativity, we examined possible drivers of increased and decreased creative activity. In a cross-sectional study, 360 participants with PD completed a questionnaire assessing self-reported creativity changes and associated factors, including personality (Big-Five, Multidimensional-Schizotypy-Scale), lifestyle (e.g., creative lifestyle, free time), and clinical (HY-scores, MoCA, dopaminergic treatments). Using machine learning (gradient-boosted decision-trees), we explained 23% of variance in creativity changes. Dopamine agonists, extraversion, free time, and a creative lifestyle since symptom onset predicted increased creativity, while disorganized schizotypy predicted decreases. The findings provide new insights for future research on creativity as part of PD's neuropsychological spectrum and for person-centered treatment.

Identifiers

PMID41258220
PMCPMC12630753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.